Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF prophylaxis for neutropenia during cervical cancer chemoradiotherapy and adjuvant chemotherapy
ChiCTR1900027429Phase 4Recruiting
- Sponsor
- Gansu Cancer Hospital
- Start
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in Cervical Cancer (CC), sponsored by Gansu Cancer Hospital. Primary endpoint: Incidence of grade III/IV neutropenia in each cycle supported by PEG-rhG-CSF. Started Nov 2019; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900027429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027429.